Ramon Mangues

Ramon Mangues is a Full Professor at the Biomedical Research Institut Sant Pau (IIB-Sant Pau) of the Hospital de Sant Pau in Barcelona. He held a 6 year position as Clinical Pharmacist at the Navarra University Clinic, and a postdoctoral and Senior Researcher positions, for 10 years, at the New York University Medical Center. He is Head of the Oncogenesis and Antitumor Drug Group, member of the Biomedical Research Network for Excellence in Nanomedicine (CIBER-BBN). Ramon Mangues is also a board member of the IIB-Sant Pau Executive Committee, borad member and Translational Research Coordinator of CIBER-BBN and of theJosep Carreras Research Institute Scientific Committee. He is an Expert Reviewer of the Swedish Research Council and the Scientific Evaluation Committee of the French National Cancer Institute. He is a member of the European Technology Platform on Nanomedicine, the American Association for Cancer Research and the New York Academy of Sciences. He is coordinator and principal investigator of research projects funded by the Spanish Government and the EU focused on targeted drug delivery in oncology, involving basic and clinical groups and small biotechnology companies. Ramon Mangues was co-founder and Scientific Advisor of Argon Pharma SL, a spin-off of the Hospital de Sant Pau. He has collaborated or currently holds Research Contracts with Merck and Co., PharmaMar/Zeltia, Esteve Laboratories, Lilly and Roche.